1 |
NCT01492816 |
Completed |
Enhancement of Connect to Protect® (C2P) |
|
- Behavioral: Community Mobilization
|
Interventional |
Not Applicable |
- University of North Carolina, Chapel Hill
- National Institute on Drug Abuse (NIDA)
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- To assess the extent to which C2P activities influence elements of the community that affect HIV-related risk prevention, testing, treatment and linkage to healthcare among youth aged 12-24 years and represent intermediate outcomes for this study.
- Examine how attributes of the SCOs relate to intermediate outcomes in order to provide guidance and recommendations to policy makers.
- Assess the trends and associations with strategies used to achieve SCOs (e.g., creating linkages, honest brokering, strategic partnering, etc.)
|
927 |
All |
16 Years and older (Child, Adult, Senior) |
NCT01492816 |
ATN 105 |
|
August 2011 |
April 2016 |
May 2016 |
December 15, 2011 |
February 28, 2017 |
|
- Children's Hospital of Los Angeles
Los Angeles, California, United States - Children's Hosp Natinal Med Center
Washington, District of Columbia, United States - University of Miami School of Medicine
Miami, Florida, United States - (and 6 more...)
|
2 |
NCT01313910 |
Completed Has Results |
CCRC: A Project of the Treatment of HIV Enteropathy With ImmunoLin® Supplements |
|
- Dietary Supplement: Immunolin®
|
Interventional |
Early Phase 1 |
- University of California, Davis
- Proliant Health & Biologicals
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Bowel Movements Per Day
- Frequency of Pro-inflammatory Bacterial Orders
- Measures of Gut Permeability
- (and 2 more...)
|
8 |
All |
18 Years and older (Adult, Senior) |
NCT01313910 |
225193 201118675 |
|
March 2011 |
August 2012 |
August 2012 |
March 14, 2011 |
June 15, 2017 |
March 3, 2017 |
- UCD CTSC Clinical Research Center (CCRC)
Mather, California, United States
|
3 |
NCT01322932 |
Completed |
Tenofovir, Emtricitabine and Efavirenz Late Switch to a Single Pill: Patients' Opinion Survey |
|
|
Observational |
|
- Policlinique Médicale Universitaire
- Centre Hospitalier Universitaire Vaudois
- Swiss HIV Cohort Study
- Gilead Sciences
|
Other / Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Patient adherence
- Adverse events and symptoms
- Treatment management
- (and 3 more...)
|
95 |
All |
18 Years and older (Adult, Senior) |
NCT01322932 |
151/10 |
|
July 2010 |
October 2011 |
February 2012 |
March 25, 2011 |
December 22, 2015 |
|
- Centre Hospitalier Universitaire Vaudois et Policlinique Medicale Universitaire
Lausanne, Vaud, Switzerland
|
4 |
NCT01687452 |
Completed |
Microparticles, Vector of Genetic Information During HIV Infection |
|
- Biological: Blood samples
|
Interventional |
Not Applicable |
- Assistance Publique Hopitaux De Marseille
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- NUMBER OF miRNAs
- Demonstrate the presence of miRNAs in microparticles
|
15 |
Male |
30 Years to 50 Years (Adult) |
NCT01687452 |
2011-A00015-36 2010-25 |
|
March 2011 |
March 2012 |
March 2012 |
September 19, 2012 |
September 1, 2014 |
|
- Assistance Publique Hopitaux de Marseille
Marseille, France
|
5 |
NCT01326195 |
Unknown † |
Dating Violence and HIV Prevention in Girls: Adapting Mental Health Interventions |
- Dating Violence
- HIV Infections
|
- Behavioral: Cognitive-Behavioral Dating Violence and HIV Prevention Group
- Behavioral: Psycho-educational Dating Violence and HIV prevention group
|
Interventional |
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Change in number (#) of unprotected sex acts
- Change in number of acts of dating violence perpetration and victimization
|
100 |
Female |
15 Years to 17 Years (Child) |
NCT01326195 |
K23MH086328 |
|
May 2009 |
February 2014 |
February 2014 |
March 30, 2011 |
March 30, 2011 |
|
- Rhode Island Hospital
Providence, Rhode Island, United States
|
6 |
NCT01327898 |
Completed |
Risk Reduction for Urban Substance Using Men Who Have Sex With Men (MSM) |
- HIV Infection
- Substance Abuse
|
- Behavioral: empowerment theory-based small group discussion
- Behavioral: individual resilience counseling
|
Interventional |
Phase 2 |
- Nova Southeastern University
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- unprotected anal intercourse events outside of primary relationships
|
515 |
Male |
18 Years to 55 Years (Adult) |
NCT01327898 |
DESPR DA024579 |
|
November 2008 |
December 2011 |
July 2014 |
April 4, 2011 |
July 25, 2014 |
|
- NSU Research Center
Miami Beach, Florida, United States - NSU Research Center
Wilton Manors, Florida, United States
|
7 |
NCT01355198 |
Completed |
Role of HIV on Glutathione Synthesis and Oxidative Stress |
- HIV Infection
- Erythrocyte Glutathione Deficiency
|
- Dietary Supplement: Cysteine (as n-acetylcysteine) and glycine
- Dietary Supplement: Cysteine/glycine
|
Interventional |
Phase 1 |
- Baylor College of Medicine
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Glutathione synthesis rates and concentrations
- Mitochondrial fuel oxidation
- Rates of fuel kinetics
- (and 3 more...)
|
10 |
Male |
21 Years to 70 Years (Adult, Senior) |
NCT01355198 |
HIV and glutathione |
|
August 2010 |
September 2011 |
September 2011 |
May 18, 2011 |
February 7, 2013 |
|
- Baylor GCRC
Houston, Texas, United States
|
8 |
NCT01317498 |
Active, not recruiting |
The VMVN Study: Virological Monitoring in Viet Nam |
|
- Other: Standard Care
- Other: Virological Monitoring
|
Interventional |
Not Applicable |
- Beth Israel Deaconess Medical Center
- Bach Mai Hospital
- Roche Molecular Systems, Inc
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Death or new/recurrent AIDS-Defining (WHO Clinical Stage IV) Illnesses
- Virological Suppression
- Time to identification and diagnosis of treatment failure.
- (and 4 more...)
|
650 |
All |
18 Years and older (Adult, Senior) |
NCT01317498 |
2010P000334 |
VMVN |
April 2011 |
April 2019 |
April 2019 |
March 17, 2011 |
May 4, 2017 |
|
- Bach Mai Hospital
Hanoi, Vietnam
|
9 |
NCT01318096 |
Unknown † |
Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected Patients |
- HBV Coinfection
- HIV Infections
|
- Drug: raltegravir and tenofovir and lamivudine
- Drug: efavirenz+tenofovir+lamivudine
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Frequency and severity of adverse events
- Change of plasma HIV-1 RNA levels
- Change of Peripheral blood CD4 cell counts
- (and 13 more...)
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT01318096 |
MSD-38154 |
|
March 2011 |
July 2012 |
September 2013 |
March 18, 2011 |
March 18, 2011 |
|
- Yunnan Provincial Hospital of Infectious Diseases/Yunnan AIDS Care Center
Kunming, Yunnan Provice, China
|
10 |
NCT01329783 |
Completed |
EuroSIDA As An External Comparator To MOTIVATE Trials |
|
|
Observational |
|
- ViiV Healthcare
- Copenhagen HIV Programme
- Pfizer
|
Industry / Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Malignancy
- Opportunistic infection
- Myocardial infarction
- (and 2 more...)
|
1181 |
All |
16 Years and older (Child, Adult, Senior) |
NCT01329783 |
A4001104 |
|
April 2007 |
March 2011 |
March 2011 |
April 6, 2011 |
May 16, 2011 |
|
|
11 |
NCT01502618 |
Completed |
Intervention for HIV-Positive Black Young Men Who Have Sex With Men (YMSM) |
- Acquired Immunodeficiency Syndrome
|
|
Interventional |
Not Applicable |
- University of North Carolina, Chapel Hill
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Produce an intervention focused on promoting critical consciousness among HIV-positive B-YMSM by using focus groups with HIV - positive B-YMSM
|
18 |
Male |
16 Years to 24 Years (Child, Adult) |
NCT01502618 |
ATN 090 |
|
August 2010 |
January 2011 |
January 2011 |
December 30, 2011 |
February 28, 2017 |
|
|
12 |
NCT01328158 |
Completed Has Results |
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection |
- Human Immunodeficiency Virus Infection
|
|
Observational |
|
- AbbVie (prior sponsor, Abbott)
- AbbVie
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of Participants With Adverse Drug Reactions
- Number of Adverse Drug Reactions
- Number of Participants With Adverse Drug Reaction by Patient Characteristic: Gender
- (and 30 more...)
|
236 |
All |
Child, Adult, Senior |
NCT01328158 |
P12-760 |
|
June 2011 |
December 2013 |
December 2013 |
April 4, 2011 |
December 22, 2014 |
December 22, 2014 |
- Site Reference ID/Investigator# 57629
Fukuoka-shi, Japan - Site Reference ID/Investigator# 57630
Hiroshima-shi, Japan - Site Reference ID/Investigator# 57631
Hokkaido, Japan - (and 20 more...)
|
13 |
NCT01309243 |
Completed Has Results |
Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults |
|
- Drug: FTC/RPV/TDF
- Drug: EFV/FTC/TDF
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48
- Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96
- Change From Baseline in CD4 Cell Count at Week 48
- (and 7 more...)
|
799 |
All |
18 Years and older (Adult, Senior) |
NCT01309243 |
GS-US-264-0110 |
|
February 2011 |
September 2012 |
February 2014 |
March 7, 2011 |
February 25, 2015 |
November 27, 2013 |
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Spectrum Medical Group
Phoenix, Arizona, United States - AHF Research Center
Beverly Hills, California, United States - (and 148 more...)
|
14 |
NCT01327547 |
Completed Has Results |
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B |
|
- Drug: Maraviroc
- Drug: Placebo
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of Participants With Grade 3 and Grade 4 Alanine Aminotransferase (ALT) Abnormalities at Week 48
- Percentage of Participants With Grade 3 and Grade 4 ALT Abnormalities Through Week 144
- Time to Development of Grade 3 and Grade 4 ALT Abnormalities
- (and 18 more...)
|
138 |
All |
18 Years and older (Adult, Senior) |
NCT01327547 |
A4001098 2010-021994-35 |
|
May 18, 2011 |
April 23, 2013 |
March 24, 2015 |
April 1, 2011 |
December 6, 2017 |
November 14, 2014 |
- The Office of Dr. Franco Antonio Felizarta, M.D.
Bakersfield, California, United States - AIDS Research Alliance
Los Angeles, California, United States - Alameda Health System - Highland Hospital
Oakland, California, United States - (and 45 more...)
|
15 |
NCT01332955 |
Completed |
Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen |
- Hepatitis C, Chronic
- HIV Infection
|
- Drug: Telaprevir
- Biological: pegIFN alfa-2a
- Drug: Ribavirin
|
Interventional |
Phase 2 |
- French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
- Janssen-Cilag Ltd.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Estimation of SVR following a 12 wks treatment by telaprevir combined with a 48 or 72 wks peginterferon-ribavirin treatment, based upon the rapid virological response, and comparison to 20% (which would correspond to a significant therapeutic benefit)
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
- Estimation of the Sustained Virological Response defined as undetectable HCV-RNA at Week 12 after the end of HCV treatment
|
70 |
All |
18 Years and older (Adult, Senior) |
NCT01332955 |
2010-023287-41 ANRS HC26 TelapreVIH |
TelapreVIH |
April 2011 |
September 2013 |
September 2013 |
April 11, 2011 |
January 23, 2014 |
|
- Service Maladies Infectieuses et Tropicales, Hôpital de la Croix-Rousse
Lyon, France
|
16 |
NCT01403298 |
Completed |
Project RAP: Family-based HIV Prevention in the Juvenile Drug Court |
|
- Behavioral: Family-Based HIV prevention
- Other: Adolescent Only Health Promotion
|
Interventional |
Not Applicable |
- University of California, San Francisco
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- adolescent HIV/STD risk
- adolescent substance use
- Scores on measures of parent-child communication (general and sex-specific),parental monitoring and family emotional environment
|
120 |
All |
13 Years to 18 Years (Child, Adult) |
NCT01403298 |
5K23DA021532 |
Project RAP |
December 2009 |
June 2013 |
June 2013 |
July 27, 2011 |
July 6, 2017 |
|
- Rhode Island Hospital
Providence, Rhode Island, United States
|
17 |
NCT01348763 |
Completed |
The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study |
|
|
Interventional |
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- maximum plasma concentration
- Changes in haematology and biochemistry laboratory tests
|
12 |
All |
18 Years to 65 Years (Adult) |
NCT01348763 |
MRV_DRV_PK 2009-014924-42 |
|
October 2011 |
February 2012 |
May 2012 |
May 5, 2011 |
May 21, 2014 |
|
- Imperial College Healthcare NHS Trust
London, United Kingdom
|
18 |
NCT01347658 |
Completed |
Drug Interactions Between Echinacea Purpurea and Etravirine |
|
- Dietary Supplement: Echinacea purpurea
|
Interventional |
Phase 1 |
- Fundacio Lluita Contra la SIDA
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- plasma concentration of etravirine.
- Clearance (CL/F)
- Volume of distribution (V/F)
- (and 5 more...)
|
15 |
All |
18 Years and older (Adult, Senior) |
NCT01347658 |
ECHI-ETRA |
|
April 2011 |
August 2011 |
August 2011 |
May 4, 2011 |
September 30, 2011 |
|
- Hospital Germans Trias i Pujol
Badalona, Barcelona, Spain
|
19 |
NCT01335620 |
Completed |
The Raltegravir 60+ Study |
|
|
Interventional |
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pharmacokinetics
- Changes in haematology, biochemistry and virology tests
- cardiovascular disease markers
- Cerebral function
|
19 |
All |
60 Years and older (Adult, Senior) |
NCT01335620 |
RTG_60 2010-022907-23 |
|
April 2011 |
December 2012 |
December 2012 |
April 14, 2011 |
May 21, 2014 |
|
- Chelsea & Westminster Hospital NHS Trust
London, United Kingdom - Imperial College Healthcare NHS Trust
London, United Kingdom
|
20 |
NCT01327482 |
Completed Has Results |
Levels of Raltegravir in the Female Genital Tissue |
|
|
Interventional |
Not Applicable |
- University of Washington
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Tissue Raltegravir Concentrations
- Plasma Raltegravir Concentrations
|
10 |
Female |
18 Years to 50 Years (Adult) |
NCT01327482 |
38681-D |
|
October 2011 |
December 2012 |
|
April 1, 2011 |
December 19, 2014 |
December 19, 2014 |
- University of Washington, Clinical Research Center
Seattle, Washington, United States
|
21 |
NCT01320176 |
Completed |
Study to Evaluate the Dosage and Safety of Two Intramuscular Injections of an Investigational Clade B HIV Vaccine |
|
- Biological: Investigational HIV vaccine dose A
- Biological: Investigational HIV vaccine dose B
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Occurrence, intensity and relationship to vaccination of solicited local and general adverse events (AEs) except fever
- Occurrence, intensity and relationship to vaccination of fever
- Occurrence, intensity and relationship to vaccination of unsolicited adverse events (AEs)
- (and 6 more...)
|
36 |
All |
18 Years to 27 Years (Adult) |
NCT01320176 |
MV1-F4-CT1 |
|
October 2010 |
November 2011 |
November 2011 |
March 22, 2011 |
February 14, 2012 |
|
- Gent University & Hospital, Center for Vaccinology
Gent, Belgium
|
22 |
NCT01322217 |
Completed |
Managerial Database II |
- Acquired Immunodeficiency Syndrome
|
|
Observational |
|
- University of North Carolina, Chapel Hill
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Collect information on for adolescents and young adults with HIV infection engaged in care at the AMTUs
- To better understand the complex relationships between adherence to medical regimens, sexual risk behavior, substance use and mental health concerns, and basic demographic and biomedical data in adolescents and young adults with HIV infection.
|
513 |
All |
12 Years to 24 Years (Child, Adult) |
NCT01322217 |
ATN 106 |
|
April 2011 |
June 2012 |
June 2012 |
March 24, 2011 |
February 28, 2017 |
|
- University of Colorado Denver
Aurora, Colorado, United States - Johns Hopkins University
Baltimore, Maryland, United States - The Fenway Institute-Fenway Health
Boston, Massachusetts, United States - (and 2 more...)
|
23 |
NCT01328041 |
Completed Has Results |
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen. |
- Infection, Human Immunodeficiency Virus
|
|
Interventional |
Phase 3 |
- ViiV Healthcare
- Shionogi
- GlaxoSmithKline
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Mean Change From Baseline in Plasma HIV-1 RNA at Day 8
- Number of Participants With HIV-1 RNA Less Than 50 Copies/mL at Week 24
- Number of Participants With HIV-1 RNA Less Than 50 Copies/mL at Week 48
- (and 16 more...)
|
183 |
All |
18 Years and older (Adult, Senior) |
NCT01328041 |
112574 |
VIKING-3 |
May 2011 |
May 2012 |
May 2015 |
April 4, 2011 |
January 7, 2016 |
July 21, 2014 |
- GSK Investigational Site
Beverly Hills, California, United States - GSK Investigational Site
Fountain Valley, California, United States - GSK Investigational Site
Los Angeles, California, United States - (and 86 more...)
|
24 |
NCT01309594 |
Unknown † |
HIV Liver Regeneration Project for HIV Patients With Cirrhosis by Autologous Bone Marrow Transplantation |
- HIV Infection
- AIDS
- Cirrhosis
|
- Procedure: Hematopoietic stem cell transplantation
|
Interventional |
Not Applicable |
- National Center for Global Health and Medicine, Japan
- Ministry of Health, Labour and Welfare, Japan
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Post-transplantation prognosis for cirrhosis
- Duration of the treatment efficacy
|
10 |
All |
20 Years to 70 Years (Adult, Senior) |
NCT01309594 |
FWA00005823-AMBi2011 UMIN000005174 |
HIV-ABMi |
March 2011 |
March 2016 |
March 2016 |
March 7, 2011 |
September 25, 2014 |
|
- National Center for Global Health and Medicine
Shinjuku, Tokyo, Japan
|
25 |
NCT01328288 |
Completed |
Progress Pediatric Study |
|
- Drug: standard ART according to the Thai Ministry of Public Health national guidelines
|
Observational |
|
- The HIV Netherlands Australia Thailand Research Collaboration
- Bamrasnaradura Infectious Diseases Institute
- Mahidol University
- (and 2 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- HIV related adverse events
- Immunological failure
- virological failure
- (and 3 more...)
|
840 |
All |
up to 18 Years (Child, Adult) |
NCT01328288 |
HIV-NAT 154 |
|
January 2009 |
September 2015 |
September 2015 |
April 4, 2011 |
February 22, 2016 |
|
- Sanpatong Hospital
Sanpathong, Chiang Mai, Thailand - HIV-NAT, Thai Red Cross AIDS Research Centre
Bangkok, Thailand - Faculty of Medicine Siriraj Hospital, Mahidol University
Bangkok, Thailand - (and 2 more...)
|
26 |
NCT01328275 |
Completed |
Progress Adult Study |
|
- Drug: standard regimens according to the Thai Ministry of Public Health national guidelines
|
Observational |
|
- The HIV Netherlands Australia Thailand Research Collaboration
- Bamrasnaradura Infectious Diseases Institute
- Sanpatong Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- HIV related adverse events
- Immunological failure
- virological failure
- (and 3 more...)
|
5600 |
All |
18 Years and older (Adult, Senior) |
NCT01328275 |
HIV-NAT 153 |
|
December 2007 |
June 2015 |
June 2015 |
April 4, 2011 |
May 11, 2016 |
|
- HIV-NAT, Thai Red Cross AIDS Research Centre
Bangkok, Thailand - Sanpatong Hospital
Chiang Mai, Thailand - Bamrasnaradura infectious disease institute
Nonthaburi, Thailand
|
27 |
NCT01335529 |
Completed |
Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin |
- HCV Coinfection
- HIV-1 Infection
|
- Drug: Boceprevir, Peg-interferon alfa 2b and Ribavirin
|
Interventional |
Phase 2 |
- French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
- Rennes University Hospital
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Sustained Virologic Response
- HCV viral load
- Predictive factors of Sustained virologic Response (SVR)
- (and 21 more...)
|
69 |
All |
18 Years and older (Adult, Senior) |
NCT01335529 |
ANRS HC27 BOCEPREVIH |
BocepreVIH |
May 2011 |
May 2014 |
May 2014 |
April 14, 2011 |
October 13, 2014 |
|
- CHU Sainte Marguerite
Marseille, France
|
28 |
NCT01319383 |
Completed Has Results |
The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART |
|
|
Interventional |
Phase 1 Phase 2 |
- University of North Carolina, Chapel Hill
- National Institutes of Health (NIH)
- Merck Sharp & Dohme Corp.
- National Institute of Allergy and Infectious Diseases (NIAID)
|
Other / NIH / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants Exhibiting an in Vivo Resting CD4+ T Cell- Associated HIV RNA (RCVL) Increase After Receiving a Single Dose of VOR 400 mg PO
- Number of Participants Exhibiting an in Vivo Resting CD4+ T-cell-associated HIV RNA (Rc-RNA) Increase Following Each of Two Multiple Dose Cycles (11 Doses/Cycle)
- Number of Participants With a Significant in Vivo Response in Resting Cell Infection (RCI) and HIV RNA After Paired Doses
- (and 4 more...)
|
25 |
All |
18 Years to 65 Years (Adult) |
NCT01319383 |
CID 0807 1U01AI095052-01 |
|
February 2011 |
March 31, 2016 |
March 31, 2016 |
March 21, 2011 |
June 29, 2017 |
June 29, 2017 |
- The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
|
29 |
NCT01339416 |
Completed Has Results |
HIV Cohort Study At Johns Hopkins University, University of North Carolina at Chapel Hill and Vanderbilt University |
|
|
Observational |
|
- ViiV Healthcare
- Johns Hopkins University
- University of North Carolina, Chapel Hill
- (and 2 more...)
|
Industry / Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Incidence Rate of Malignancies
- Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
- Incidence Rate of Myocardial Infarction
- (and 4 more...)
|
8202 |
All |
Child, Adult, Senior |
NCT01339416 |
A4001106 |
|
March 2009 |
May 2013 |
May 2013 |
April 20, 2011 |
April 21, 2014 |
April 21, 2014 |
|
30 |
NCT01339403 |
Completed Has Results |
Kaiser Permanente HIV Cohort Study |
|
- Other: non-interventional trial
|
Observational |
|
- ViiV Healthcare
- Kaiser Permanente
- Pfizer
|
Industry / Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Incidence Rate of Malignancies
- Incidence Rate of Myocardial Infarction and Ischemia
- Incidence Rate of Acquired Immunodeficiency Syndrome (AIDS)-Defining Opportunistic Infections
- (and 5 more...)
|
282368 |
All |
18 Years and older (Adult, Senior) |
NCT01339403 |
A4001105 |
|
February 2009 |
October 2013 |
October 2013 |
April 20, 2011 |
April 3, 2015 |
April 3, 2015 |
|
31 |
NCT01330342 |
Unknown † |
Evolution of Cellular and Viral Resistance in HIV-infected Patients With Lymphoma |
|
|
Observational |
|
|
Other |
- Observational Model: Case Control
|
- Development of multi-drug resistance (in terms of expression of transmembrane transporters and their transcriptional regulators) in HIV-infected patients with lymphoma.
- Development of mutations in the HIV genome that may confer resistance to future treatment for HIV.
|
40 |
All |
Child, Adult, Senior |
NCT01330342 |
SSAT 042 |
SSAT042 |
May 2011 |
May 2014 |
May 2014 |
April 6, 2011 |
June 11, 2012 |
|
- St Stephen's Centre
London, United Kingdom
|
32 |
NCT01317277 |
Completed |
Personalized Text Messages to Improve Antiretroviral Treatment (ART) Adherence in HIV+ Methamphetamine Users |
|
- Behavioral: individualized Texting for Adherence Building (iTAB)
- Behavioral: Psychoeducation
|
Interventional |
Not Applicable |
- University of California, San Diego
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Adherence to Antiretroviral Medication
|
75 |
All |
18 Years and older (Adult, Senior) |
NCT01317277 |
1R34DA031058-01A1 |
iTAB |
April 2011 |
June 2014 |
June 2014 |
March 17, 2011 |
June 26, 2014 |
|
- Hnrc-Tmarc
San Diego, California, United States
|
33 |
NCT01380613 |
Completed |
Neighborhoods, Networks, Depression, and HIV Risk |
|
- Behavioral: Workshop
- Behavioral: Workshop control
|
Interventional |
Phase 2 |
- Johns Hopkins Bloomberg School of Public Health
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Change from Baseline in Depressive Symptoms Measured by the CESD Scale at 6 months
- Change from Baseline in Depressive Symptoms Measured by the CESD Scale at 12 months
- Change from Baseline in Sex Risk Behavior Based on Number of Sex Partners and Condom Use at 6 months
- (and 3 more...)
|
965 |
All |
18 Years to 55 Years (Adult) |
NCT01380613 |
DESPR-DA022961-03 R01DA022961 |
Workshop |
September 2007 |
July 2013 |
July 2013 |
June 27, 2011 |
September 5, 2013 |
|
- Lighthouse Studies @ Peer Points- JHSPH
Baltimore, Maryland, United States
|
34 |
NCT01328743 |
Completed |
Brief Alcohol Intervention for HIV-Infected Men Who Have Sex With Men (MSM) in a Primary Care Setting |
|
- Behavioral: Brief alcohol intervention
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of alcoholic drinks consumed
- Number of heavy drinking days
|
180 |
Male |
18 Years and older (Adult, Senior) |
NCT01328743 |
NIAAA-P01-AA019072-1 |
|
May 2011 |
July 2016 |
August 2016 |
April 5, 2011 |
July 6, 2017 |
|
- Fenway Health
Boston, Massachusetts, United States
|
35 |
NCT01315301 |
Unknown † |
Optimal Time to Initiate Antiretroviral Therapy in HIV & TB Coinfected Adults Being Treated for Tuberculosis |
- Acquired Immunodeficiency Syndrome
- Tuberculosis
|
- Other: Comparison of different treatment strategies
|
Interventional |
Not Applicable |
- Karolinska Institutet
- Addis Ababa University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- mortality
- Tuberculosis-Immune Reconstitution Inflammatory Syndrome
- New AIDS defining clinical events
- (and 2 more...)
|
450 |
All |
18 Years to 65 Years (Adult) |
NCT01315301 |
SWE-2007-270 |
TB-HAART |
August 2008 |
January 2012 |
March 2012 |
March 15, 2011 |
March 15, 2011 |
|
- Tikur Anbessa (Black Lion) Hospital
Addis Ababa, Ethiopia
|
36 |
NCT01315353 |
Completed |
HPV Test-and-Treat-Strategy Versus Cytology-based Strategy for Prevention of CIN2+ in HIV-Infected Women |
|
- Procedure: cervical cryotherapy
- Procedure: Loop Electrosurgical Excision Procedure (LEEP)
|
Interventional |
Phase 2 |
- AIDS Clinical Trials Group
- National Institute of Allergy and Infectious Diseases (NIAID)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Cervical intraepithelial neoplasia (CIN2+) (CIN2, CIN3 or invasive cancer) by biopsy 26 weeks through 130 weeks after randomization
- Detection of high risk (hr)-HPV by the Abbott Real Time high-risk HPV assay (aHPV) at study visits.
- Cervical cytology results at study visits.
- (and 3 more...)
|
467 |
Female |
18 Years and older (Adult, Senior) |
NCT01315353 |
ACTG A5282 1U01AI068636 |
|
March 2012 |
February 1, 2017 |
February 1, 2017 |
March 15, 2011 |
March 1, 2017 |
|
- Gaborone Prevention/Treatment Trials CRS (12701)
Gaborone, Botswana - Molepolole Prevention/Treatment Trials CRS (12702)
Molepolole, Botswana - Les Centres GHESKIO CRS (30022)
Bicentenaire, Port-au-Prince, Haiti - (and 11 more...)
|
37 |
NCT01315054 |
Unknown † |
A Methadone Maintenance Treatment Outcome Study in Three Provinces in China |
- HIV
- Hepatitis C
- Syphilis
- Herpes Simplex Type II
|
- Behavioral: MMT provider dosage training
- Behavioral: targeted counseling
- Other: national guidelines
|
Interventional |
Not Applicable |
- Centers for Disease Control and Prevention
- National Center for AIDS/STD Control and Prevention, China CDC
|
U.S. Fed / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- MMT retention rate
- Illicit opioid use rate
- HIV, HCV, syphilis and HSV-2 infection seroconversion rate
- (and 4 more...)
|
7700 |
All |
18 Years and older (Adult, Senior) |
NCT01315054 |
CDC-CGH-6014 CN_09_217 |
|
May 2011 |
December 2014 |
December 2014 |
March 15, 2011 |
March 17, 2014 |
|
- National Center for HIV/STD Prevention and Control, China CDC
Beijing, China
|
38 |
NCT01352117 |
Active, not recruiting Has Results |
Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma |
- HIV-1 Infection
- Kaposi's Sarcoma
|
- Drug: efavirenz/emtricitabine/tenofovir disoproxil fumarate
- Drug: etoposide
|
Interventional |
Phase 3 |
- AIDS Clinical Trials Group
- National Institute of Allergy and Infectious Diseases (NIAID)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Kaposi Sarcoma (KS) Status at Week 48 Compared to Study Entry
- KS Progressive Disease at Week 48 Compared to Study Entry
- KS Partial Response at Week 48 Compared to Study Entry
- (and 22 more...)
|
192 |
All |
18 Years and older (Adult, Senior) |
NCT01352117 |
ACTG A5264 1U01AI068636 AMC 067 |
REACT-KS |
November 18, 2011 |
March 16, 2016 |
December 2019 |
May 11, 2011 |
November 17, 2017 |
July 31, 2017 |
- Instituto de Pesquisa Clinica Evandro Chagas (12101)
Rio de Janeiro, Brazil - AMPATH at Moi Univ. Teaching Hosp. Eldoret CRS (12601)
Eldoret, Kenya - Walter Reed Project - Kenya Med. Research Institute Kericho CRS (12501)
Kericho, Kenya - (and 7 more...)
|
39 |
NCT01317784 |
Completed |
Behavioral Science Aspects of Rapid Test Acceptance |
- HIV
- Hepatitis C
- Hepatitis B
- Syphilis
|
- Device: Rapid tests for HIV, HCV, HBV, and syphilis
- Device: HIV/HCV
- Device: HIV/syphilis
- Device: HIV only
|
Interventional |
Not Applicable |
- California State University, Long Beach
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Screening
|
- Test choice profile
- Return for standard test results
|
1200 |
All |
18 Years and older (Adult, Senior) |
NCT01317784 |
07373710 R01DA030234 |
BSARTA |
May 2011 |
June 2014 |
August 2014 |
March 17, 2011 |
July 29, 2015 |
|
- Center for Behavioral Research and Services
Long Beach, California, United States
|
40 |
NCT01312181 |
Unknown † |
HealthCall:Brief Intervention to Reduce Non-injecting Drug Use in HIV Primary Care Clinics |
- Mental and Behavioral Disorders Due to Multiple Drug Use and Use of Other Psychoactive Substances: Harmful Use
|
- Behavioral: HealthCall and Motivational Interviewing
- Behavioral: Motivational Interviewing (MI)
- Behavioral: HIV/AIDS health education
|
Interventional |
Phase 1 Phase 2 |
- Research Foundation for Mental Hygiene, Inc.
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary outcome variable is drug use, assessed at baseline and repeatedly during follow-up so that change can be analyzed.
|
390 |
All |
18 Years and older (Adult, Senior) |
NCT01312181 |
R01DA024606 |
|
June 2011 |
August 2015 |
December 2015 |
March 10, 2011 |
November 16, 2015 |
|
- Mt Sinai Spencer Cox Center for Health
New York, New York, United States - Institute for Advanced Medicine, Mt. Sinai services
New York, New York, United States
|
41 |
NCT01316744 |
Unknown † |
Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain |
|
- Drug: ketamine hydrochloride
- Other: pharmacogenomic studies
- Other: questionnaire administration
- (and 2 more...)
|
Interventional |
Phase 3 |
- University of Glasgow
- National Cancer Institute (NCI)
|
Other |
- Allocation: Randomized
- Masking: Double
- Primary Purpose: Supportive Care
|
- Time to treatment failure
- Initial treatment benefit (at day 4 of assessment period of 16 days) using the sensory component of the McGill Short-Form Questionnaire
- Difference in overall pain between the study arms based on the visual-analogue score
- (and 5 more...)
|
214 |
All |
18 Years and older (Adult, Senior) |
NCT01316744 |
CDR0000696704 CRUK-KPS-2008-01 EU-21012 EUDRACT-2007-002080-27 ISRCTN-49116945 |
|
April 2009 |
October 2011 |
|
March 16, 2011 |
May 13, 2011 |
|
- Royal Brompton Hospital
London, England, United Kingdom - Edinburgh Cancer Centre at Western General Hospital
Edinburgh, Scotland, United Kingdom - Beatson West of Scotland Cancer Centre
Glasgow, Scotland, United Kingdom
|